Hosted on MSN1mon
Hit and Miss for CDK4/6 Inhibitor in Recurrent Brain Cancer
In a preliminary study of patients with progressive brain metastases and CDK pathway alterations, the CDK4/6 inhibitor palbociclib (Ibrance) extended the PFS in more than half of patients.
Cure Today24d
Understanding the Best Practices Associated With CDK4/6 Therapy in Breast Cancer
Dr. Sara M. Tolaney discusses breast practices associated with CDK4/6 inhibitors for the treatment of breast cancer. At the 42nd Annual Miami Breast Cancer Conference, Dr. Sara M. Tolaney sat down for ...
EurekAlert!2d
TRIM4 modulates the ubiquitin-mediated degradation of hnRNPDL and weakens sensitivity to CDK4/6 inhibitor in ovarian cancer
Ovarian cancer, a leading cause of death among gynecological malignancies, has a poor prognosis and low 5-year survival rate, ...
eLife16d
Ezh2 Delays Activation of Differentiation Genes During Normal Cerebellar Granule Neuron Development and in Medulloblastoma
Using an unbiased approach, this important study discovered a role of Ezh2 in the differentiation of granule neuron precursors, the cell of origin for Shh group of medulloblastoma. Furthermore, the ...